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Abstract: Alzheimer’s disease and Parkinson’s disease are two common neurodegenerative 
diseases of the elderly people that have devastating effects in terms of morbidity and mortality. 
The predominant form of the disease in either case is sporadic with uncertain etiology. The 
clinical features of Parkinson’s disease are primarily motor deficits, while the patients of 
Alzheimer’s disease present with dementia and cognitive impairment. Though neuronal death 
is a common element in both the disorders, the postmortem histopathology of the brain is very 
characteristic in each case and different from each other. In terms of molecular pathogenesis, 
however, both the diseases have a significant commonality, and proteinopathy (abnormal 
accumulation of misfolded proteins), mitochondrial dysfunction and oxidative stress are the 
cardinal features in either case. These three damage mechanisms work in concert, reinforcing 
each other to drive the pathology in the aging brain for both the diseases; very interestingly, 
the nature of interactions among these three damage mechanisms is very similar in both the 
diseases, and this review attempts to highlight these aspects. In the case of Alzheimer’s disease, 
the peptide amyloid beta (Aβ) is responsible for the proteinopathy, while α-synuclein plays a 
similar role in Parkinson’s disease. The expression levels of these two proteins and their aggrega-
tion processes are modulated by reactive oxygen radicals and transition metal ions in a similar 
manner. In turn, these proteins – as oligomers or in aggregated forms – cause mitochondrial 
impairment by apparently following similar mechanisms. Understanding the common nature 
of these interactions may, therefore, help us to identify putative neuroprotective strategies that 
would be beneficial in both the clinical conditions.
Keywords: proteinopathy, amyloid beta, oxidative stress, α-synuclein, mitochondrial 
dysfunction
Introduction
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two commonest 
neurodegenerative diseases of the elderly that follow a relentlessly downhill course 
until the patients succumb to the illness.1–3 Both the diseases appear predominantly 
in a sporadic fashion, but a small subset of patients in either AD or PD suffer from 
the familial variety of the disease with well-defined mutations.1–3 The clinical pre-
sentations of AD and PD are different, but both are progressive over the years, with 
PD primarily presenting with motor deficits and AD presenting with dementia and 
cognitive decline.1–3 Both the diseases show characteristic but complex histopatho-
logical findings in the brain at autopsy. However, there are overlapping similarities 
in AD and PD in terms of molecular pathogenesis, which we attempt to highlight in 
this review.4–6
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The pathogenesis of sporadic AD or PD is highly complex, 
but several cardinal cellular and molecular mechanisms, such 
as proteotoxicity, mitochondrial dysfunction and oxidative 
stress, have been suggested based on postmortem studies in 
patients and evidence acquired from various experimental 
models.7–10 Although abnormal accumulation of proteins of 
altered conformation is considered as the most characteristic 
molecular signature of AD or PD, it is highly unlikely that 
only proteinopathy acts as the driving force of the pathol-
ogy, while others such as oxidative stress and mitochondrial 
dysfunction are secondary consequences. Instead, it is 
plausible that they represent interacting damage pathways 
that culminate in neuronal death and degeneration. Thus, 
the cross talk among proteinopathy, oxidative stress and 
mitochondrial dysfunctions on the one hand and the genetic 
or nongenetic factors that trigger these damage mechanisms 
on the other have to be analyzed critically to obtain a deeper 
understanding of the pathogenesis of AD and PD. The 
literature is replete with studies that demonstrate the varied 
aspects of proteotoxicity culminating in neurodegeneration 
in AD or PD, as well as the detailed biophysical aspects 
of altered protein conformation and aggregation in these 
disorders; these aspects are not covered in this review.11–14 
This review instead analyzes in detail the possible inter-
actions among proteotoxic mechanisms, oxidative stress 
and mitochondrial functional impairment in relation to the 
pathogenesis of AD or PD.
Proteinopathy: links with 
oxidative stress and mitochondrial 
dysfunction
The accumulation of a specific protein, either the wild-type 
or a mutant variety, in excess with altered conformations 
that facilitate aggregation is a hallmark of many neuro-
degenerative diseases, including AD and PD, which has 
been often termed as proteinopathy.15 The accumulation of 
proteins can occur intraneuronally (tau or α-synuclein) or 
outside the cells (amyloid beta [Aβ] peptide) and can take 
on varied histopathological forms.15 Some elaboration of this 
concept in the context of the pathogenesis of AD and PD 
is necessary before the cross talk of proteinopathy with 
oxidative stress or mitochondrial function can be analyzed 
in the individual disease. The accumulation of a specific 
toxic protein may result from the transcriptional activation 
or enhanced translation of a specific mRNA or a diminished 
degradation rate of the protein through impairment of the 
proteasomal or lysosomal pathway.15–20 In some conditions, 
the mutant gene produces an abnormal product that is not 
readily cleared by the protein degradation machinery, lead-
ing to its accumulation, and a similar thing can happen if the 
protein is posttranslationally modified because of changes in 
the internal milieu of the cell, such as the redox status and 
the activity of kinases.19,20 The accumulation of the wild-type 
or the mutant protein in excess amount can trigger confor-
mational alterations, eg, helix to β-strand, which facilitate 
oligomerization and self-aggregation. The chaperones and 
co-chaperones, such as heat shock protein (Hsp)70, Hsp90, 
Hsp40 and others, normally prevent misfolding of intracel-
lular proteins, but excess accumulation, mutations or redox 
modifications of such proteins may overwhelm this system 
and, additionally, there may be altered expression levels 
of these chaperones.21,22 The toxic effect of these protein 
oligomers or aggregates on diverse functions of the cell 
organelles defines the term proteotoxicity, but it is also likely 
that even the monomeric forms of some of these proteins 
could be toxic when present in excess amounts.
The molecular links of proteinopathy and proteotoxicity 
with oxidative stress could be varied and complicated. For 
example, reactive oxygen species (ROS)-responsive tran-
scription factors can alter the expression of genes encoding 
such toxic proteins or the enzymes involved in the synthesis, 
processsing or degradation of such proteins.23 Furthermore, 
the oxidative stress can directly inactivate the proteasomal 
system to varying degrees, especially the 26S proteasome 
that is responsible for the degradation of the toxic protein 
aggregates; many details of such ROS-mediated regulation 
of proteasomal degradation are currently being elucidated.24,25 
The lysosomal removal of the toxic proteins may also be 
affected by ROS, which are known to have complex inter-
actions with the phenomenon of autophagy.25 Furthermore, 
ROS may also potentiate the oligomerization of proteins such 
as α-synuclein and amyloid beta, or these proteins may inter-
act with transition metals or other components to generate 
further ROS.26,27 Similarly, proteotoxicity and mitochondrial 
functional impairment are also interdependent. There is 
evidence to show that aggregated or oligomerized proteins – 
or even monomers of amyloid beta or α-synuclein – cause 
varied mitochondrial damages, such as impairment of bio-
energetics, altered fusion/fission and impaired mitophagy, 
as evident in studies with isolated mitochondria, cultured 
cells and postmortem brain samples.28–31 The dysfunctional 
mitochondria resulting from proteotoxicity in turn may 
produce excess ROS, triggering cellular death pathways. 
These myriad interactions of oxygen radicals, mitochondria 
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and toxic protein oligomers are analyzed in the context of 
AD and PD separately to understand their importance in the 
disease pathogenesis.
Alzheimer’s disease
Currently, ~24 million people across the globe suffer from 
AD, which is characterized by progressive dementia and 
deficits in multiple cognitive domains.2 The diagnosis of 
probable AD is made clinically supported by magnetic 
resonance imaging (MRI) findings, but a more accurate 
antemortem diagnosis is possible with positron emission 
tomography (PET) scan of amyloid deposition or decreased 
18F-fluoro-2-deoxyglucose uptake or cerebrospinal fluid 
(CSF) analysis of amyloid beta peptide 1–42 (Aβ42), tau 
and phosphorylated tau. The diagnosis can be confirmed by 
postmortem analysis of brain histopathology showing dif-
fuse neuronal and synaptic loss with extracellular amyloid 
plaques of different varieties and intraneuronal formation of 
neurofibrillary tangles.2
Proteinopathy: amyloid beta and tau
The toxic proteins that are deposited extracellularly in the 
brain as amyloid and neuritic plaques are called amyloid beta 
peptides (Aβ42 and Aβ40 peptides, in particular) derived 
from a precursor known as amyloid precursor protein (APP) 
through the sequential actions of two proteases.3,32 These 
two proteases, β and γ secretases, cleave out the peptides 
from APP, which is a type I membrane protein expressed 
as several isoforms in the brain.32,33 The expression, pro-
cessing and intracellular trafficking of APP and amyloid 
beta peptides in the trans-Golgi network, endosomes and 
plasma membrane are well-established events, and the 
multiple toxicities of the amyloid peptides – especially in 
the soluble oligomeric form – are thought to spearhead the 
pathogenesis of AD (amyloid cascade hypothesis).3,34 Thus, 
based on postmortem data and experimental studies in cell 
lines, primary culture of hippocampal neurons and transgenic 
animal models, it has been suggested that oligomers of amy-
loid beta peptides can lead to mitochondrial dysfunction, 
calcium dysregulation, inflammatory reaction, endoplasmic 
reticulum (ER) stress and oxidative damage to trigger the 
process of neurodegeneration.33,34 Apart from the amyloid 
beta proteinopathy, another characteristic of AD pathology 
is the accumulation of phosphorylated tau proteins within 
the neurons, which also contributes to synaptic dysfunction 
and axonal degeneration.35,36 The reasons for the abnormal 
accumulation of amyloid beta protein or phosphorylated tau 
in the sporadic AD brain are not entirely clear, but it would 
be interesting to accrue evidence on how oxidative stress may 
interact with the proteinopathy of the AD brain.
Oxidative stress affects amyloid beta 
accumulation
The evidence of oxidative damage in postmortem AD brain 
is quite compelling, with significant accumulation of oxida-
tive damage markers of lipid, protein and DNA, increased 
accumulation of transition metals such as Fe, Cu and Zn as 
well as impaired antioxidant defense.37 The recent redox 
proteomics analysis of the postmortem AD brain has demon-
strated oxidative damage to key enzymes involved in energy 
metabolism, neurotransmitter-related proteins, mitochondrial 
proteins and proteasomal components.38
The cross talk between oxidative stress and amyloid 
beta proteinopathy may occur via multiple ways affecting 
transcription of the APP gene or translation of APP mRNA, 
processing and degradation of APP and amyloid beta pep-
tides as well as interactions of APP with transition metals. 
The promoter sites of the APP gene have been mapped in 
different species, and several transcription factors such as 
HSF-1 and NF-kB, which are responsive to ROS, can bind 
here and induce APP expression.39,40 The involvement of 
NF-kB and ROS in upregulating APP expression has been 
demonstrated in various experimental models.41,42 The post-
transcriptional control of APP expression has been elucidated 
in great detail, and APP mRNA contains a 5′-untranslated 
region (UTR) stem–loop arrangement of the iron-responsive 
element (IRE), where the IRE-binding protein (IREBP) binds 
and downregulates translation. In the presence of increased 
level of intracellular iron, IREBP dissociates from the binding 
site at the 5′-UTR of APP mRNA, leading to translational 
upregulation in a manner similar to the translational regula-
tion of ferritin by iron.43 Transition metals such as Fe are 
important catalysts for ROS production, and elevated levels 
of iron have been reported from postmortem analyses of AD 
brains; thus, an obvious connection is implied between oxida-
tive stress and APP production in the AD brain.44 The major 
processing enzymes of APP in the amyloidogenic pathway 
are β-secretase (BACE1) and γ-secretase.3,32 There are several 
binding sites for redox-responsive transcription factors, such 
as Sp1, NF-kB, and HIF-1α, near the promoter region of 
BACE1 and the expression of BACE1 may be modulated by 
ROS.45,46 However, the effect on gene expression of BACE1 
by such transcription factors is often very complex, and both 
up- and downregulation of BACE1 gene have been reported 
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after binding of such transcription factors depending on the 
cell types and the physiological or experimental conditions 
of the cells.45,47 There are multiple reasons for such varied 
response following binding of these transcription factors. 
For example, the nature of the subunits binding to the NF-kB 
binding sites may determine whether up- or downregulation 
of BACE1 gene takes place.45 Similarly, though NF-kB is a 
redox-sensitive transcription factor, its interaction with ROS 
is complex and may lead to either activation and enhanced 
nuclear translocation in certain experimental conditions or 
decreased nuclear binding in others.48 However, oxidative 
stress-induced increased BACE1 activity has been reported in 
many experimental systems.46,49 In several studies, products 
of oxidative damage (such as 4-hydroxynonenal [4-HNE]) 
or oxidants (such as H
2
O
2
 and iron–ascorbate mixture) have 
been shown to increase BACE1 activity through activation of 
stress-activated protein kinase.50,51 In a more extensive study, 
it has been shown that oxidative stress-induced increase in 
BACE1 activity both in cultured cells and in experimental 
animals requires the involvement of γ-secretase and activation 
of the JNK/c-jun pathway.52 Additionally, oxidative stress 
increases BACE1 activity at the translational level involv-
ing double-stranded RNA-dependent protein kinase (PKR) 
and eukaryotic initiation factor-2 (eIF2) phosphorylation.53 
Such data do suggest that oxidative stress contributes to the 
increase in BACE1 activity in AD. The γ-secretase enzyme 
complex, composed of presenilin1 (PS1), nicastrin, PEN2 
and APH1, is also essential for the release of Aβ42 from 
APP, and its activity is enhanced by oxidative stress through 
upregulation of PS1.52
In different experimental models, oxidative stress has 
been shown to increase the production and accumulation of 
Aβ42, which could be accounted for by its effect on APP 
expression and processing.54 Additionally, in AD, the clear-
ance of amyloid beta from the brain is affected as a result of 
oxidative damage. The clearance of amyloid beta from the 
brain is regulated by the low-density lipoprotein receptor-
related protein 1 (LRP1) and the receptor for advanced 
glycation end products (RAGE).55–57 The LRP1 exists in 
two forms; the membrane-bound form is responsible for the 
removal of cerebral amyloid beta to the circulation across the 
blood–brain barrier and is expressed in neurons, astrocytes, 
vascular endothelial cells and smooth muscle cells, while 
the soluble form binds the amyloid beta in the peripheral 
circulation.55,56 RAGE, present in the blood–brain barrier, 
on the other hand, may allow the reentry of amyloid beta 
from the peripheral circulation. Under oxidative stress, the 
membrane-bound LRP1 is altered, preventing the clearance 
of amyloid beta from the brain; furthermore, the oxidized 
soluble LRP1 fails to bind the circulating amyloid beta 
properly, allowing its reentry into the brain.57
Amyloid beta induces oxidative stress
Multiple mechanisms are operative in initiating the oxida-
tive damage in the AD brain, but in particular, amyloid 
beta-induced ROS generation has been well documented in 
a large number of experimental studies with cultured cells, 
subcellular fractions, experimental animals and cell-free 
chemical systems.58–60 Both Aβ42 and Aβ40 can bind transi-
tion metals in a redox-active form through several amino acid 
residues that include His6, His13 and His14, and the related 
coordination chemistry has been elaborately described.61 The 
bound metal ions can take part in redox-cycling reactions 
that generate ROS, and the mechanism – though not fully 
understood – may require Met35 of the peptide or another 
reducing agent in the surroundings.61 These experimental 
studies are significant because of the postmortem evidence 
of increased levels of transition metals such as Fe, Cu and 
Zn in the AD brain, especially near the plaque, which implies 
that amyloid beta-mediated ROS production could be impor-
tant in AD pathogenesis. However, based on scattered but 
substantial experimental evidence, an opposite view posits 
an antioxidant and protective role of amyloid beta, whereby 
the peptide scavenges the reactive radicals of lipid oxida-
tion, prevents the formation of ROS through sequestration 
of the transition metals or even blocks the mitochondrial 
production of oxygen free radicals.62 Apart from this direct 
production of ROS by bound redox-active metals, amyloid 
beta may lead to increased production of ROS intracellularly 
and to subsequent neuronal death through the involvement 
of ASK 1.58 In neuronal culture, amyloid beta increases ROS 
production presumably through the activation of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, but enhanced mitochondrial production of oxygen 
radicals, which is preventable by mitochondria-targeted anti-
oxidants, has been demonstrated.63,64 The other mechanisms 
of amyloid beta-induced ROS production involve microglial 
activation and priming by the soluble or fibrillar form of 
the peptide, as observed in primary cultures of microglia 
or coculture of microglia and neurons.65,66 The activated 
microglial cells produce both ROS and proinflammatory 
cytokines such as interleukin (IL)-6, IL-1β, tumor necrosis 
factor (TNF)-α and initiate the inflammatory response in AD 
brain following activation by amyloid beta acting through a 
variety of receptors.67 Thus, the microglia contain a B-type of 
scavenger receptor, called CD36, which has been shown to 
act as a receptor for fibrillar amyloid beta, and the activation 
of this receptor by the peptide leads to increased microglial 
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ROS production, cytokine expression and phagocytosis.67,68 
Others have shown that amyloid beta-induced microglial 
activation and ROS production is mediated by MAC-1 recep-
tor and PI3K, causing activation of NADPH oxidase.69 The 
central role of NADPH oxidase in microglial production of 
ROS induced by amyloid beta has been highlighted in many 
other studies.65,69
Oxidative stress and tau phosphorylation
The formation of neurofibrillary tangles from intracel-
lular accumulation of hyperphosphorylated tau protein is 
another characteristic feature of AD pathogenesis, which 
contributes significantly to the axonal degeneration and 
synaptic dysfunction associated with these disorders.70,71 The 
microtubule-associated tau protein has multiple phosphoryla-
tion sites in the C-terminal and in the proline-rich regions of 
the protein, and a number of kinases – especially GSK3β and 
CDK5 – can phosphorylate the latter.71 Several phosphatases, 
predominantly PP2A, PP1 and PP2B, can dephosphorylate 
tau.71 In AD, the increased phosphorylation of tau protein is 
the result of increased activities of GSK3β and CDK5, with 
an associated decrease in PP2A activity, but the reasons for 
such alterations in the activities of kinases and phosphatases 
in this disease condition are not clear. In different experimen-
tal models, the role of oxidative stress on tau phosphoryla-
tion has been investigated. Chronic oxidative stress in the 
form of glutathione depletion has been shown to increase 
tau phosphorylation in cultured M17 neuroblastoma cells 
through activation of JNK and p38 as well as diminished 
activity of PP2A.72 In cultured cortical neurons, amyloid 
beta-induced tau phosphorylation is mediated by oxidative 
stress through the involvement of p38 kinase and the phenom-
enon is blocked by the antioxidant trolox.73 Similarly, in rat 
primary cortical neuronal culture, a combination of Fe2+ and 
H
2
O
2
 causes increased phosphorylation of tau, presumably 
through the activation of GSK3.74 On the contrary, there are 
reports of decreased phosphorylation of tau under oxidative 
stress in different experimental models through modulations 
of kinases (such as GSK3 or CDK5) or phosphatases (such as 
PP1), and thus, the relationship between oxidative stress and 
tau phosphorylation is somewhat uncertain at present.75,76
Amyloid beta and mitochondrial 
functions
Mitochondrial dysfunction is a key mechanism in the patho-
genesis of AD, and studies with both postmortem AD brains 
and various experimental models have corroborated this.77 
For example, a variety of structural changes such as frag-
mented mitochondria with abnormal cristae, impairment of 
bioenergetics along with diminished cytochrome oxidase, 
α-ketodehydrogenase, pyruvate dehydrogenase activities, 
decreased adenosine triphosphate (ATP) synthesis, mitochon-
drial membrane depolarization, increased ROS production 
and altered mitochondrial biogenesis and dynamics have been 
reported.77,78 Since mitochondrial oxidative phosphorylation 
is the major source of ROS, it is reasonable to assume that 
mitochondrial dysfunction contributes significantly to genesis 
of oxidative stress in AD brain. However, the interrelation-
ship between mitochondrial dysfunction and proteotoxicity 
is the subject of intense research. In particular, extensive 
studies have been conducted using transgenic AD models, 
postmortem AD brain, cultured cells and isolated mitochon-
dria to elucidate how amyloid beta or its soluble oligomers 
interact with mitochondria through multiple mechanisms. 
In transgenic AD mice, progressive accumulation of amy-
loid beta occurs in the brain mitochondria, with diminished 
activities of respiratory chain enzymes and decreased oxygen 
consumption rate; similar accumulations of amyloid beta also 
take place in different AD-affected brain regions in postmor-
tem AD brain.79 Immunofluorescence staining and confocal 
microscopy, as well as other techniques, have identified that 
amyloid beta (Aβ) binds to mitochondrial short-chain alcohol 
dehydrogenase, which is known as Aβ-binding alcohol dehy-
drogenase (ABAD).79 The other protein with which amyloid 
beta may remain in association is Hsp60, which is a marker of 
the mitochondrial matrix.79 The accumulation of amyloid beta 
may lead to inhibition of mitochondrial peptidasome (PreP), 
which removes the presequences from the N-terminals of 
mitochondrially targeted proteins.80 The impaired process-
ing of these preproteins may change the protein profile of 
mitochondria, leading to multiple functional anomalies 
of this organelle in AD.80 Another possible mechanism of 
multiple functional impairments of mitochondria in AD is 
the blockage of protein import channels of this organelle by 
APP, preventing the entry of nuclear DNA-coded proteins 
of mitochondria, including the subunits of the respiratory 
chain complexes.30,81 The soluble oligomers of amyloid beta, 
however, can impair functions of isolated mitochondria incu-
bated in vitro, which may possibly be related to its interac-
tions with many other mitochondrial proteins, such as adenine 
nucleotide translocase (ANT), components of translocase of 
outer membrane (TOM) or translocase of inner membrane 
(TIM), cyclophilin D, uncoupler protein (UCP) and others.82 
The interactions of soluble oligomers of amyloid beta with 
lipid biomembranes have been studied in depth by several 
groups, which indicates that membrane-spanning channels 
(Aβ channels) could be created by such oligomers, allowing 
different ions to pass through these channels.83,84 If such a 
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Figure 1 Amyloid beta proteinopathy in AD brain.
Notes: Oxidative stress causes increased expression of APP and BACe1, leading to accumulation of Aβ42. The clearance of Aβ42 from the brain is also retarded by oxidative 
stress. On the other hand, the multiple interactions of Aβ42 with mitochondria, microglia and metal ions lead to further oxidative stress. Arrows suggest interactions; a line 
with an end bar indicates retardation.
Abbreviations: Aβ42, amyloid beta peptide 1–42; AD, Alzheimer’s disease; APP, amyloid precursor protein; BACe1, β-secretase; eiF2, eukaryotic initiation factor-2; iRe, 
iron-responsive element; LRP1, low-density lipoprotein receptor-related protein 1; PKR, double-stranded RNA-dependent protein kinase; RAGe, receptor for advanced 
glycation end products; ROS, reactive oxygen species.
mechanism is operative in the interactions of amyloid beta 
oligomers with mitochondria, it may explain some of the 
toxic effects of amyloid beta on this organelle. The other 
interesting finding in the context of amyloid beta-induced 
mitochondrial dysfunction in astrocytes is the involvement 
of cytosolic and calcium-independent phospholipase A2 
in this process.85 Furthermore, in astrocytes, amyloid beta 
has been reported to activate NADPH oxidase to enhance 
ROS production, which in turn may cause mitochondrial 
dysfunction and glutathione depletion in both neurons and 
astrocytes.86
Figure 1 summarizes the various possible mechanisms in 
AD brain through which oxidative stress leads to an accumu-
lation of amyloid β42, which in turn impairs mitochondrial 
function and interacts with metal ions in microglia.
Parkinson’s disease
The disease presents clinically as a triad of bradykinesia, 
muscular rigidity and resting tremor in elderly people, 
with a prevalence of 425 per 100,000 in the age group of 
64–75 years, which increases further with advancing age.1,87 
As the disease gradually worsens, many secondary symptoms 
develop, such as postural instability; difficulty in swallowing, 
breathing and speaking; sleep disturbance; depression and 
dementia. Majority of PD patients (.95%) suffer from 
the sporadic variety of the disease, while mutations in 18 
chromosomal loci (PARK 1, PARK 2, PARK 3, PARK 4, 
PARK 5 and so on) lead to familial PD (,5%).1,88 Some 
mutations as in α-synuclein (PARK 1), Parkin (PARK 2), 
PINK1 (PARK 6) or DJ-1 (PARK 7) give rise to monogenic 
forms of familial PD, with either autosomal dominant or 
recessive inheritance.1,88 The pathological hallmark of the 
disease is the degeneration of the dopaminergic (DAergic) 
neurons of the substantia nigra projecting into the striatum, 
but extensive postmortem studies have now established that 
the neurodegeneration affects many other areas of the brain, 
beginning in the olfactory bulb and dorsal nucleus of the 
vagus and progressing sequentially to the pons, medulla, 
midbrain, mesocortical areas and, finally, the neocortex.89 In 
sporadic and some types of familial PD, the neurodegenera-
tion is associated with the development of round eosinophilic 
inclusion bodies called Lewy bodies within the soma of the 
neurons and the appearance of spindle-shaped or thread-like 
structures within the cell processes called Lewy neurites.89,90 
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Both Lewy bodies and Lewy neurites are immunoreactive 
for α-synuclein.89,91
Proteinopathy in PD
The major protein component of the intraneuronal Lewy 
bodies that are present in the degenerating neurons of 
sporadic PD is α-synuclein, which is a small protein of 
140 amino acids (14.1 kDa) abundantly present in the 
brain.4,90 The physiological function of this protein is not fully 
known, but it may play a pivotal role in synaptic plasticity and 
the vesicular transport and release of neurotransmitters.90,92 
This protein, in the native state, remains in an unfolded form 
and has a propensity to bind to liposomes, synthetic mem-
branes and membranes of the organelles.90,92,93 The binding 
to synthetic membranes through the interaction of the acidic 
phospholipids and the N-terminal lysine-rich segment of the 
peptide causes a conformational change from the unfolded 
form to partially helical structures, as observed through 
a variety of biophysical techniques in vitro.90,92,93 The oli-
gomerization and subsequent fibrillization of α-synuclein is 
initiated and propagated through the conformational change 
of the natively unfolded or the membrane-bound helical form 
of the protein to the β-strand conformation, and dimerization 
may be a key step in this process.90,92–94 The process occurs 
in a concentration-dependent manner and is also affected by 
membrane binding or posttranslational modifications such 
as phosphorylation, proteolysis, oxidative modification and 
metal binding.90,92–94
The accumulation of α-synuclein in vulnerable regions 
in the PD brain could be because of overexpression through 
transcriptional (eg, DNA methylation status) and posttran-
scriptional mechanisms (iron acting through IRE and IREBP 
at the 5′-UTR of the mRNA) as well as by the diminished 
degradation of the protein through proteasomal and lyso-
somal pathways.18,95–98 The ubiquitin–proteasomal system 
(UPS) is a major pathway of intracellular protein degradation 
and is particularly responsible for the removal of damaged 
or misfolded proteins.99 The UPS uses a group of enzymes 
(E1, E2 and E3) to conjugate a chain of multiple ubiquitin 
(a small protein of 76 amino acids with a highly conserved 
sequence) units to target proteins destined for degrada-
tion, and subsequently these tagged proteins are delivered 
to the 26S/20S proteasomal complex for ATP-dependent 
degradation.100 The proteasomal impairment has been sug-
gested to be an important mechanism of neurodegeneration 
in PD and has been studied extensively in experimental 
models as well as in postmortem brains, especially because 
mutations in several genes, such as Parkin and ubiquitin 
C-terminal hydrolase L1 (UCH-L1) coding for the UPS 
enzymes, give rise to some varieties of familial PD.88,101–104 
In the substantia nigra of the postmortem PD brain, sig-
nificant loss of the α-subunit of the 26S/20S proteasomal 
complex, coupled with impaired activity of the 20S subunit, 
and diminished levels of endogenous proteasomal activators 
have been observed.99 Moreover, the systemic administration 
of natural and synthetic proteasomal inhibitors to rats has 
been shown to give rise to striatal dopamine (DA) depletion 
and nigral DAergic neuronal death.102 Similarly, the pro-
teasomal inhibitor lactacystin induces apoptosis in cultured 
SH-SY5Y cells through translocation of the cytosolic Bax to 
mitochondria.105 Furthermore, the overexpression of mutant 
α-synuclein in differentiated PC12 cells causes decreased 
proteasomal activity and increased sensitivity of the cells 
to apoptotic death following exposure to subtoxic concen-
trations of the proteasomal inhibitor.104 Thus, proteasomal 
impairment has been suggested to play a pivotal role in the 
pathogenesis of PD, but several inconsistencies have also 
been pointed out with regard to neurodegeneration caused by 
proteasomal inhibitors.98 However, in general, it is plausible 
that proteasomal inactivation could be the mechanism for 
the accumulation of α-synuclein in the sporadic PD brain, 
and in turn, the latter in its aggregated form may further 
downregulate the 26S proteasomal activity presumably by 
interacting with the 19S cap. The other relevant mechanisms 
for the impairment of UPS in PD may include DA-derived 
ROS and quinones.106,107
Several missense mutations (A53T, A30P and E46K) or 
duplication or triplication of the α-synuclein gene results 
in the familial form of PD with autosomal dominance.4,88 
A genome-wide association study has also indicated that 
common variations of the α-synuclein gene constitute a 
risk factor for PD.108 Lentivirus-mediated overexpression 
of wild-type or mutant human α-synuclein after injection 
into substantia nigra in rats leads to DAergic neurodegen-
eration, with the formation of inclusion bodies immunore-
active for α-synuclein.109 Recombinant adeno-associated 
virus-mediated expression of α-synuclein (wild or mutant) 
in mouse substantia nigra triggers progressive neurodegen-
eration, and interestingly, both wild and mutant varieties of 
α-synuclein cause similar degrees of pathology.110 Similarly, 
fibrillar rat α-synuclein injected into mice striatum causes 
neurodegeneration, with Lewy body-like structures in sub-
stantia nigra and other areas.111 When Lewy body-enriched 
fractions from postmortem PD brains are injected into 
substantia nigra or striatum of mice or monkeys, human 
α-synuclein is seen to be internalized within neurons, 
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triggering a progressive neurodegeneration that is dependent 
upon the expression of endogenous α-synuclein of the 
animal.112 Furthermore, in cell-based models, overexpres-
sion or accumulation of α-synuclein induces cell death or 
potentiates DA-induced loss of cell viability.113 Thus, there 
is a growing body of evidence of α-synucleinopathy as the 
pivotal mechanism of PD neurodegeneration, even though 
the mechanism of toxicity is not clearly understood.
Alpha-synuclein and mitochondrial 
dysfunction in PD
A most characteristic pathology of PD, as mentioned already, 
is the impairment of mitochondrial functions at different 
levels.4,5,114 The original postmortem finding was a decrease in 
complex I activity in the substantia nigra of PD patients, and 
subsequently, the activities of other respiratory chain com-
plexes have been shown to be decreased to a variable extent 
in the platelets and skeletal muscles of PD subjects.115–117 
Furthermore, mitochondrial fusion and fission, responsible 
for the dynamic morphology and functional quality of the 
organelle, are possibly altered in sporadic PD, as suggested 
from studies in cell-based models of this disease, including 
cybrids.5,118,119 Cybrids are created by the fusion of human 
neuroblastoma cells or teratocarcinoma cells depleted of 
endogenous mitochondrial DNA (mtDNA) with platelets 
from PD subjects.119,120 Such cybrids also show a variety 
of defects in respiratory chain activity, ROS production 
and susceptibility to mitochondrial toxins.119 Several toxins 
and endogenously available molecules, such as rotenone, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), para-
quat, 6-hydroxy-DA (6-OHDA) and DA, which are known 
to impair mitochondrial functions, can produce PD-like 
neurodegeneration in animal models coupled with behavioral 
deficits.7,121–124 In cultured DAergic cell lines such as PC12 
and SH-SY5Y, MPTP, DA or 6-OHDA trigger apoptotic 
cell death with profound mitochondrial dysfunctions.122,124 
Accumulation of mitochondrial DNA mutations has been 
observed in laser-microdissected nigral neurons from 
postmortem PD brains.125 Mutations in several genes, such 
as Parkin and PINK1, cause familial forms of PD, and the 
proteins coded by these genes are known to maintain the 
functional quality of mitochondria through mitophagy.126 
Thus, altered mitophagy could be a possible mechanism of 
the mitochondrial dysfunction observed in PD, and this topic 
needs some elaborate analysis. The detailed mechanism of 
mitophagy, a type of macroautophagy to remove dysfunc-
tional and damaged mitochondria, has been extensively 
studied in both yeast and mammalian systems. In yeast, 
mitophagy requires several proteins, including Uth1, ancient 
ubiquitous protein 1 (Aup1), autophagy 32 (Atg32) and 
so on; Atg32, which is considered the mitophagy-specific 
receptor of mitochondria, interacts with Atg11 during the 
formation of the autophagosome.126,127 In mammals, includ-
ing humans, mitophagy is a more complex phenomenon 
and, along with mitochondrial fusion and fission processes, 
it regulates the quality control of the mitochondria. Several 
proteins, such as BCL2, adenovirus E1B 19 kDa-interacting 
protein 3-like (BniP3), and BNIP3-like protein X (Nix), 
which are proapoptotic proteins belonging to the Bcl-2 
family, are involved in the process of mitophagy, and these 
proteins through their C-terminal transmembrane domains 
get embedded in the mitochondrial outer membrane.126,127 
Many other proteins, such as the Fun14 domain-containing 
protein 1 (Fundc1), Atg7, Parkin and PINK1, have been 
shown to be involved in mitophagy under different experi-
mental conditions.127,128 In particular, the PINK1 and Parkin 
signaling for mitophagy is important in the context of 
PD pathogenesis, and the inducer for mitophagy could be 
mitochondrial membrane depolarization.127,128 It has been 
shown conclusively that PINK1 accumulates on damaged 
and depolarized mitochondria and further recruits Parkin by 
translocating it from the cytosol to the mitochondrial surface, 
triggering mitophagy.128–131 There is some evidence, though 
not conclusively established, that Parkin is phosphorylated by 
PINK1, which also activates the E3 ubiquitin ligase activity 
of Parkin, leading to ubiquitination of the mitochondrial 
membrane proteins.128,129,131 Some recent studies have indi-
cated that PINK1 accumulation, along with Parkin recruit-
ment on damaged mitochondria, depends on the bioenergetic 
state of the cell, and ATP may have a key involvement in 
this process.132,133 Furthermore, other studies have indicated 
complex interactions of Parkin, PINK1 and α-synuclein in 
regulating mitochondrial dynamics and mitophagy.134,135 
Overall, it appears that altered mitophagy and mitochon-
drial dynamics play a key role in PD pathogenesis, with 
the involvement of Parkin, PINK1 and α-synuclein, but the 
molecular scenario is far from clear as of now.
The trigger for mitochondrial alterations in sporadic PD 
in the absence of environmental toxins such as paraquat 
or MPTP is not so far convincingly established, but ROS 
and toxic quinones derived from oxidation of DA could 
be important in this respect.124 On the other hand, there is 
enough evidence to suggest that the interactions of mitochon-
dria with α-synuclein through multiple mechanisms could 
play a determining role in the PD-associated dysfunction of 
this organelle.114,136 The N-terminal region of α-synuclein 
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contains a cryptic sequence containing several positively 
charged residues for targeting the mitochondria, and the 
protein enters the organelle through interaction with TOM40 
and remains associated with the inner membrane.114,136,137 The 
accumulation of α-synuclein within mitochondria has been 
shown to inhibit mitochondrial complex I activity.114,137 In 
postmortem PD brain, increased accumulation of α-synuclein 
within the mitochondria has been shown in the regions of 
the substantia nigra and striatum, but not in the cerebellum, 
and this study has further demonstrated the interaction of 
α-synuclein with complex I both in postmortem PD brain 
tissue and in cultured cell lines.138 Similarly, aggregated 
α-synuclein has been shown to inhibit complex I activity in 
cybrids, leading to impaired ATP synthesis and mitochon-
drial respiration.139 On the other hand, the interaction of 
α-synuclein with mitochondria, which leads to membrane 
depolarization and impaired ATP synthesis but without 
changes in the activities of the respiratory complexes, 
has been clearly demonstrated in vitro, and apparently, 
α-synuclein interacts with components of the mitochondrial 
permeability transition pore (mPTP).28,140 It has been further 
shown that this interaction of α-synuclein with mPTP in 
cultured SH-SY5Y cells triggers cell death, which could be 
prevented by α-synuclein gene knockdown.140 Furthermore, 
α-synuclein has been shown to inhibit mitochondrial fusion, 
resulting in fragmented mitochondria in cultured cells over-
expressing the protein, and the phenomenon can be blocked 
by coexpression of Parkin, PINK1 and DJ-1.141
Alpha-synuclein and oxidative stress: 
interactions in PD pathogenesis
Oxidative stress is considered to be an important element 
of PD pathogenesis as is evident from the accumulation of 
oxidative damage markers and transition metals such as Fe 
in the postmortem PD brain, especially in the substantia 
nigra.142,143 In experimental models of PD, enhanced pro-
duction of ROS has been observed, with alterations of the 
antioxidant enzyme levels.144 Mitochondrial dysfunction 
caused by α-synuclein could be a source of enhanced produc-
tion of ROS, as has been observed in several experimental 
models.140,145 Overexpression of wild or mutant α-synuclein 
in SH-SY5Y cells has also been shown to increase the intra-
cellular level of ROS.146 On the other hand, iron – which 
facilitates ROS production and catalyzes peroxidative 
damage to biomolecules – accumulates in the substantia 
nigra of PD brains in excess amounts and causes translational 
upregulation of α-synuclein.96 Furthermore, the binding of 
transition metals such as Fe and Cu to α-synuclein has been 
studied with a variety of biophysical techniques in different 
studies, and apparently, such binding may lead to enhanced 
cytotoxicity of α-synuclein through multiple mechanisms.147 
For example, Fe can trigger the formation of large sodium 
dodecyl sulfate (SDS)-resistant oligomers of α-synuclein 
capable of forming membrane-spanning channels, which 
may partly explain the toxicity of α-synuclein on intracel-
lular organelles.147 The binding of iron to α-synuclein may 
also lead to the formation of H
2
O
2
 through redox reactions.147 
The binding of Cu to α-synuclein also enhances the toxicity 
of the latter, as has been shown in cultured SH-SY5Y cells 
overexpressing α-synuclein.146 Since DAergic neurons are 
particularly affected in PD, it has been suggested that DA 
oxidation products such as ROS and toxic quinones could 
contribute to PD pathology.124,148 In this context, it is interest-
ing to note that the interaction of α-synuclein with DA has 
been studied by several groups, indicating a modulatory role 
of DA oxidation products on α-synuclein oligomerization 
and cytotoxicity.149 In a very elaborate study, it has been 
shown that in human DAergic neurons and rat DAergic cell 
lines exposed to paraquat, increased accumulation and aggre-
gation of α-synuclein occurs, which is crucially dependent 
upon the activity of NADPH oxidase, implicating the role 
of ROS in the process.150 This study has further shown that 
the systemic injection of paraquat in rats causes increased 
protein expression of α-synuclein and NADPH oxidase, 
along with the accumulation of oxidative damage markers 
in the substantia nigra, which can be abolished by knocking 
down NADPH oxidase (Nox1) gene by adeno-associated 
virus-mediated overexpression of a specific short hairpin 
RNA (shRNA).150 The knockdown of Nox1 also prevents 
the nigral DAergic neuronal loss after paraquat treatment 
of rat.150 Another interesting cross talk between oxidative 
stress and α-synuclein is presumable when oxidatively 
modified protein becomes partially resistant to degradation 
by the UPS or chaperone-mediated autophagy, leading to 
accumulation of the misfolded protein.151 Several types of 
oxidative modifications of α-synuclein have been demon-
strated, such as nitration of tyrosine residues, oxidation of 
methionine residues and covalent adduct formation with 
4-hydroxynonenal.151 Such oxidatively modified α-synuclein 
proteins, in general, inhibit oligomerization and fibril for-
mation by the native monomer and instead may give rise to 
“off-pathway” oligomers, but the toxic consequence of this 
has not been clearly established.151 The various mechanisms 
leading to the accumulation of α-synuclein in the PD brain 
and the toxicity of this protein in monomeric or oligomeric 
form in the mitochondria are highlighted in Figure 2.
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Conclusion
This review has shown that the three cardinal processes of 
molecular pathogenesis of AD and PD, such as proteinopa-
thy, mitochondrial dysfunction and oxidative stress, are 
interdependent phenomena with extensive and reinforcing 
cross talking, but there is no discernible arrangement of 
upstream and downstream events. Thus, targeting one of the 
three processes separately with a putative drug is unlikely 
to be successful as a neuroprotective measure. On the other 
hand, multiple drugs or other measures targeted to these 
pathways taken in combination may be beneficial in pre-
venting the progress of these diseases. Currently, intensive 
research is going on using animal and cell-based models to 
elucidate how these molecular damage pathways finally lead 
to the programmed cell death of neurons in AD and PD. It 
is perhaps more prudent to identify the triggers that lead an 
aging brain to follow the pathway of AD or PD pathology, 
and apparently, the metabolic and environmental risk factors 
of these diseases identified in clinical cases may provide 
us the clue.
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